Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | MEDI5117 |
Trade Name | |
Synonyms | MEDI-5117 |
Drug Descriptions |
MEDI5117 is an anti-IL6 monoclonal antibody, which inhibits IL6 autocrine signaling, potentially leading to decreased tumor cell growth (PMID: 26744529, PMID: 27237319). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Cisplatin + Gemcitabine + MEDI5117 | Cisplatin Gemcitabine MEDI5117 | 0 | 0 |
Docetaxel + MEDI5117 | Docetaxel MEDI5117 | 0 | 0 |
Doxorubicin + MEDI5117 | Doxorubicin MEDI5117 | 0 | 0 |
Gefitinib + MEDI5117 | Gefitinib MEDI5117 | 0 | 0 |
MEDI5117 | MEDI5117 | 0 | 0 |
MEDI5117 + Paclitaxel | MEDI5117 Paclitaxel | 0 | 0 |
MEDI5117 + Pemetrexed Disodium | MEDI5117 Pemetrexed Disodium | 0 | 0 |
MEDI5117 + Topotecan | MEDI5117 Topotecan | 0 | 0 |